Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A244-rgp120
- Development stage
- Phase 1
- Lead developer
- U.S. Army Medical Research and Development Command
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
A244-rgp120 is a recombinant HIV-1 envelope glycoprotein 120 (rgp120) derived from a Clade E (CRF01_AE) strain, originally identified in Thailand. It was developed as a key component of the AIDSVAX B/E vaccine, which was used in the landmark RV144 Phase 3 clinical trial. Research led by Phil Berman at the University of California, Santa Cruz, has focused on optimizing the production of A244 using CRISPR-engineered MGAT CHO cell lines to ensure the presence of high-mannose glycans, which are essential for the binding of broadly neutralizing antibodies (bNAbs). The protein is currently being evaluated in various prime-boost regimens, including trials like RV306, often in combination with novel adjuvants such as ALFQ or other vaccine candidates like IHV01, to enhance the breadth and durability of the immune response against HIV-1.
- Other names
- HIV-1 A244 rgp120HIV1 A244 rgp120HIV 1 A244 rgp120CRF01_AE gp120rgp120/HIV-1 A244AIDSVAX B/E component
02
Targets
HIV-1 gp120-specific B-cell receptorgp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)
Beyond the preview
Go deeper on A244-rgp120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A244-rgp120.